Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 7/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | CASP9 | P55211 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indigotindisulfonate SCHEMBL3652418 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL3680504 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL186296 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL9107944 | 0.98 | CA12 (0.49) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL5455215 | 0.96 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL29387846 | 0.96 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL2727226 | 0.96 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL186297 | 0.96 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL2732840 | 0.96 | CA12 (0.50) | CA12CA1CA2CA9CASP3 | |
| Indigotindisulfonate SCHEMBL29694234 | 0.95 | CA12 (0.49) | CA12CA1CA2CA9CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230190731-A1 | FORMULATION COMPRISING HIF PROLYL HYDROXYLASE INHIBITORS | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-06-22 | — | — | US | claimed |
| EP-4121009-A1 | FORMULATION COMPRISING HIF PROLYL HYDROXYLASE INHIBITORS | Zydus Lifesciences Limited (IN) | 2023-01-25 | — | — | EP | claimed |
| WO-2021186356-A1 | FORMULATION COMPRISING HIF PROLYL HYDROXYLASE INHIBITORS | CADILA HEALTHCARE LIMITED (IN) | 2021-09-23 | — | — | WO | claimed |
| EP-3708154-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | Fibrogen, Inc. (US) | 2020-09-16 | — | — | EP | claimed |
| EP-3003284-B1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN INC (US) | 2020-02-12 | — | — | EP | claimed |
| US-20160120859-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN, INC. (US) | 2016-05-05 | — | — | US | claimed |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | GERO PTE LTD (SG) | 2023-06-22 | — | — | US | disclosed |
| US-20220054474-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN, INC. | 2022-02-24 | — | — | US | disclosed |
| WO-2021194396-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | OBSHCHESTVO S OGRANICHENNOY OTVESTVENNOSTYU "GERO" (RU) | 2021-09-30 | — | — | WO | disclosed |
| EP-3708154-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | Fibrogen, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| US-10765672-B2 | Pharmaceutical formulations of a HIF hydroxylase inhibitor | FIBROGEN, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| EP-3003284-B1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN INC (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20190008846-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN, INC. | 2019-01-10 | — | — | US | disclosed |
| EP-3003284-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | Fibrogen, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014197660-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2009038340-A1 | PHARMACEUTICAL COMPOSITION OF ARTEMISIA EXTRACT USING GASTRO-RETENTIVE DRUG DELIVERY SYSTEM AND ITS ORAL SUSTAINED RELEASE FORMULATION | DONG-A PHARM.CO., LTD. (KR) | 2009-03-26 | — | — | WO | disclosed |
| EP-0966268-B1 | CROSS-LINKED PLANT PROTEIN PARTICLES, IN PARTICULAR MICROPARTICLES OR NANOPARTICLES, PREPARATION METHOD AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS CONTAINING SAME | COLETICA (FR) | 2003-05-21 | — | — | EP | disclosed |
| US-6352693-B1 | PESTICIDE, CARRAGEENAN, AND GLYCERIN IN A POWDERED CROP, DEXTRIN, A SUGAR, A FAT AND/OR A FATTY OIL; CONTROLLING ANTS AND COCKROACHES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-03-05 | — | — | US | disclosed |
| EP-0966268-A1 | CROSS-LINKED PLANT PROTEIN PARTICLES, IN PARTICULAR MICROPARTICLES OR NANOPARTICLES, PREPARATION METHOD AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS CONTAINING SAME | COLETICA (FR) | 1999-12-29 | — | — | EP | disclosed |
| WO-1999003450-A1 | CROSS-LINKED PLANT PROTEIN PARTICLES, IN PARTICULAR MICROPARTICLES OR NANOPARTICLES, PREPARATION METHOD AND COSMETIC, PHARMACEUTICAL OR FOOD COMPOSITIONS CONTAINING SAME | COLETICA (FR) | 1999-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | AGER, CKMT1A; CKMT1B, GLA | CA12 2964/4885CA1 3823/4885CA2 3136/4885 |
| US-20190008846-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | HIF1AN, EGLN3, EGLN2 | CA12 2745/4885CA1 1683/4885CA2 627/4885 |
| US-20220054474-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | HIF1AN, EGLN3, EGLN2 | CA12 2745/4885CA1 1683/4885CA2 627/4885 |
| US-10765672-B2 | Pharmaceutical formulations of a HIF hydroxylase inhibitor | HIF1AN, EGLN3, EGLN2 | CA12 2745/4885CA1 1683/4885CA2 627/4885 |
| US-20230190731-A1 | FORMULATION COMPRISING HIF PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | CA12 2533/4885CA1 1894/4885CA2 719/4885 |
| US-20160120859-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | HIF1AN, EGLN3, EGLN2 | CA12 2745/4885CA1 1683/4885CA2 627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.